Shionogi's RSV antiviral shows promise in hVIVO trial
LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an ...
hVIVO wins contract for RSV drug human trial for Inhalon Biopharma
(Alliance News) - hVIVO PLC on Monday said it has signed a contract with Inhalon Biopharma Inc to test its antiviral candidate to treat respiratory syncytial virus. The London-based contract research ...
The Pharma Letter4d
hVIVO plans challenge trial for RSV antiviral candidate
UK contract research organization hVIVO (AIM: HVO) is gearing up to test an inhaled antiviral candidate, IN-002, for ...